And the move will shake up the orthopaedic robotics scene.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
But launch is unlikely before 2024.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Welcome to the calm before the Covid-19 storm.
A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.